At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 94 enrolled
Drug / intervention
FGF Receptor +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Study of LY2874455 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Patients With Advanced Cancer.
In Brief
A Phase 1 clinical trial evaluating FGF Receptor and Phosphate Binders for Advanced Cancer. Completed, enrolled 94 participants across 3 sites in 2 countries.
Detailed Summary
The study is to determine the recommended Phase 2 regimen of study drug that may be safely administered to participants with advanced and or metastatic cancer. The study consists of two parts: a dose escalation and a dose confirmation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Cancer
CountriesAustralia, South Korea
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedSep 2010
Enrollment StartDec 2010
Primary CompletionAug 2014
Study CompletionFeb 2015
TodayJul 2026
First PostedSep 30, 2010
Enrollment StartDec 1, 2010
Primary CompletionAug 1, 2014
Study CompletionFeb 1, 2015
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 15.8 years ago
Interventions
FGF Receptordrug
LY2874455 administered orally.
Phosphate Bindersdrug